Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...